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Abstract
Background: Deterioration in bone health is one of the presenting symptoms of Multiple Myeloma (MM), a
cancer of plasma cells. As a consequence of this condition, patients suffer bone pain and bone damage and
report cancer-related fatigue, resulting in deterioration in their quality of life. Evidence in patients with solid
tumours shows promise for the positive effects of physical activity on quality of life. However, in the case
of patients with MM a better understanding of the association between physical fitness and quality of life
factors is still required. Therefore, this cohort study aims to objectively and longitudinally assess activity and
fitness levels in patients with MM in order to explore their role in bone health, fatigue and quality of life for
this patient population.
Methods/Design: The study is a prospective cohort study of MM patients in remission to assess physical
activity, fatigue and bone health. Clinical markers of health, self-reported measures of psychological and
physical well-being, and lifestyle behaviours are assessed at baseline, 3, 6 and 12 months. At each time point,
patients complete cardiopulmonary exercise testing (CPET) along with a series of objective tests to assess
physical fitness (eg accelerometry) and a number of self-report measures. A complementary qualitative study
will be carried out in order to explore patients’ desire for lifestyle advice and when in their cancer journey
they deem such advice to be useful.
Discussion: This study will be the first to prospectively and longitudinally explore associations between
physical fitness and well-being, bone health, and fatigue (along with a number of other physical and clinical
outcomes) in a cohort of patients with MM with the use of objective measures. The findings will also help
to identify time points within the MM pathway at which physical activity interventions may be introduced
for maximum benefit.
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Background
Multiple Myeloma (MM) accounts for around 10 % of
all haematological cancers [1], with approximately 5500
new cases each year in the UK [2]. It is incurable, but
effective disease-directed therapies are extending life
expectancy and patients often enter a long plateau phase
(remission), where they require no (or only mainten-
ance) treatment. A main presenting feature of MM is
abnormal bone metabolism with around 80 % of patients
demonstrating bone morbidity [3], putting them at high
risk of fracture, pain and vertebral collapse, leading to
skeletal deformity, muscle wasting and deconditioning
[4]. Cancer-related fatigue (CRF) is another clinical fea-
ture observed in a very large proportion, with symptoms
often persisting long after treatment has ceased [5]. CRF
has been identified as one of the most distressing cancer
symptoms, with some patients rating it even above pain
[6–8] deterring patients from further treatment, impact-
ing recovery and survival rates [9]. The aetiology of
fatigue in cancer is multifactorial, including anaemia,
systemic reaction to tissue injury caused by the disease,
infections, sleep disturbance, psychosocial factors [5].
An emerging body of literature demonstrates that
chemotherapy is extremely detrimental to health related
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fitness, and inefficiency of the cardiovascular system
may contribute to fatigue and impair quality of life.
Given good evidence that physical activity can improve
fitness, bone health and reduce fatigue in other popula-
tions (including other cancers), it is feasible that physical
activity could be of particular importance in improving
outcomes for patients with MM. In a retrospective study
88 MM survivors were asked to report their exercise be-
haviour during and post-treatment. Although this study
was limited by the use of self-report and recall, activity
levels were extremely low with 6.8 % and 20.4 % of par-
ticipants meeting minimum activity guidelines during
and off-treatment respectively [10] (which is likely an
over-estimate). However, more physical activity was re-
lated to higher scores on all domains of quality of life
[10]. In a qualitative study patients expressed strong
desire for physical activity advice, but fear of initiating
exercise was a barrier [11]. Studies using objective mea-
sures of physical activity and health-related fitness, along
with clinical and patient reported outcomes, are required
to increase our understanding of how activity levels and
fitness change over time post-diagnosis; how these fac-
tors relate to bone health and fatigue and when and how
patients would like lifestyle advice to be provided are
also required before we can provide tailored exercise in-
terventions to this unique population.
Cohort studies with a focus on physical activity and
fitness in cancer survivors are limited generally, indeed
to our knowledge only one study; the AMBER cohort of
breast cancer patients [12], is currently collecting longi-
tudinal data on objectively measured activity, along with
clinical outcomes. Here we describe the Myeloma – Ad-
vancing Survivor Cancer OuTcomes (MASCOT) cohort
study. To our knowledge, MASCOT is the first study to
gather longitudinal objective data on physical activity,
fitness and clinical and patient reported outcomes in
multiple myeloma.
The aims of the MASCOT cohort study are to exam-
ine objectively measured activity levels (and health
related fitness) at multiple time points following treat-
ment, and to examine how activity and fitness relate to
markers of bone health, fatigue and a number of clinical,
physical and patient reported outcomes. This will form a
comprehensive study into the benefits of physical activity
on the survivorship outcomes of patients with Multiple
Myeloma.
Methods
Study design
The MASCOT cohort was approved by the NRES Com-
mittee London – Queen Square (13/LO/1105) and all
patients are required to provide informed written con-
sent prior to participation. The study is a prospective co-
hort study of MM patients in plateau phase to assess
physical activity, fatigue and bone health. Clinical
markers of health as well as self-reported measures of
psychological and physical well-being are also assessed
at baseline, 3, 6 and 12 months. At each time point
patients complete a clinical assessment, followed by a
physical assessment. Flow of patients through the study
is shown in Fig. 1.
Participants
Eligibility criteria are: MM (1) having stable disease
(confirmed by a blood test) for at least 6 weeks and
either off treatment or on maintenance or consolidation
treatment (2) performance status 0–2, as per Eastern
Cooperative Oncology Group scoring system (ECOG,
[13]) and (3) an ability to provide informed consent. Ex-
clusion criteria are: 1) having spinal instability, 2) having
had recent surgery, 3) a poor performance status (ECOG
>2), 4) abnormal resting electrocardiogram (ECG) 5) re-
ceiving erythroprotein treatment, 6) at risk of pathological
fracture (Mirel’s score >7), 7) unstable angina, 8) musculo-
skeletal disease limiting mobility or 9) cognitive impair-
ment that impedes ability to complete questionnaires.
Patients are also ineligible if they are involved in another
lifestyle study.
Recruitment
Recruitment began in June 2014 at the specialist mye-
loma clinic at University College London Hospital
(UCLH) and Royal Free Hospital and is planned to take
place over 28 months. If required, patients will also be
recruited from St Bartholomew’ Hospital. Approximately
150–200 patients who are in plateau phase are seen an-
nually in each centre. Evidence from a pilot exercise
intervention study at UCLH suggested that 80 % of
potentially eligible patients would pass eligibility screen-
ing [14] and our initial MASCOT screening results have
been very similar (>75 % have been eligible). Clinicians
identify potential participants in clinic or multidisciplin-
ary team meetings (MDTs) and screen for eligibility,
then patients are approached by the research team and
provided with information sheets. To date, we have
approached 230 eligible patients, of whom 100 have
agreed to participate. Once patients are enrolled, the
myeloma clinical team are informed and a letter is is-
sued informing their general practitioner (GP).
Outcome measures
Primary (physical activity, fitness, bone health and fa-
tigue) and secondary outcome measures (well-being,
quality of life, diet, self-efficacy, mood, sleep, body com-
position, muscle strength and endurance) are assessed at
baseline, 3 months and 6 months and 12-months.
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Physical activity and sedentary behavior
Physical activity is assessed using a waist-worn Actigraph
wGT3X-BT accelerometer for 7 days at each time point.
The Actigraph is a valid and reliable motion sensor that
provides an accurate measure of total physical activity
and time spent sedentary, in light and in moderate and
vigorous physical activity (MVPA). The time spent in ac-
tivity is expressed in metabolic equivalent units (METs).
METs are calculated by dividing the steady state VO2 by
3.5 mL kg−1 min−1 with the following cut off points <3
METs; 3–5.99 METs; 6.0–8.99 METs; > = 9 METs for
sedentary, light, moderate and vigorous activity respect-
ively [15]. The Actigraph is worn in conjunction with
Bluetooth® Heart Rate Monitor which records 24 h heart
rate. Patients’ participation in PA is also assessed using
The Godin Leisure-Time Exercise Questionnaire
(GLTEQ, [16] that is widely used in cancer survivors and
has acceptable reliability and validity. Patients also
complete the GLTEQ via email, telephone or post on a
monthly basis throughout the study. The Actigraph is
also worn overnight around the wrist to provide a meas-
ure of sleep patterns.
Cardiorespiratory fitness and strength
Cardiorespiratory fitness is assessed using the MetaLy-
zer® CPET system (Cortex Biophysik GmbH) and Corival
cycle ergometer LODE using VO2peak and anaerobic
threshold. Exercise testing is terminated before normal
physiologic limitation if the patient shows any of the in-
dications as outlined in the American Thoracic Society/
American College of Chest Physicians (ATS/ACCP)
statement on cardiopulmonary exercise testing (CPET,
[17]. The level of exertion is assessed using Borg scale
[18]. Isometric muscle strength (hand grip strength) is
measured with a hand held dynamometer. Three mea-
surements are taken from each arm and the mean of
these used. Strength endurance of lower limbs is
assessed using a leg press to calculate the maximum load
the patient can lift ten times [19]. Lung function is
assessed by spirometery and blood pressure taken.
Bone health and fatigue
Blood samples are taken at each time point for measure-
ment of markers of bone health (serum levels of OPG &
soluble RANKL, serum TRACP-5b, serum TRACP-5b,
Fig. 1 Flow of patients through the lifestyle in myeloma study
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osteoclacin levels) and vitamin D status. Inflammatory
marker CRP is also measured. Fatigue is reported using
the 13 item Fatigue Scale of the Functional Assessment
of Chronic Illness Therapy (FACIT, [20]. The FACIT is
considered appropriate for use with patients with any
form of cancer and has been shown to be responsive to
change in clinical and observational studies [20].
Anthropometrics
Body weight (kg) and percentage body fat and lean mass
are assessed using Bioelectrical impedance (TANITA
scales model MC-980). Height without shoes is mea-
sured using a Leicester height measure and body mass
index (BMI) calculated (weight kg/height2).
Health and lifestyle
Quality of life (QoL) is reported using the Functional
Assessment of Cancer Therapy-General (FACT-G),
which has subscales for physical, functional, emotional
and social/family wellbeing and it has shown positive re-
sponse to exercise in other cancers [21]. In the current
study we are using the emotional and functional well-
being subscales of FACT-G. Patients also complete the
Hospital and Anxiety and Depressions scale (HADS,
[22], widely used to measure emotional distress in can-
cer patients [23] and report on their sleep patterns using
Pittsburgh Sleep Quality Index (PSQI, [24]. In addition,
patients complete the Health and Lifestyle Questionnaire
[25], which explores diet and assesses desire for lifestyle
advice and patients ‘experience of receiving such advice
during their care, whether they would like to receive it,
at which time-point(s), from whom and in which for-
mat(s). Patients’ views on when health behaviour advice
should be offered during cancer journey and what fac-
tors facilitate and prevent the introduction of behaviour
change are also explored in qualitative interviews.
We also assess patients’ confidence in managing their
illness and taking part in physical activity (Chronic
Disease Self-Efficacy Scales, [26]. Self-efficacy has been
found to be correlated with the success in adopting life-
style changes, including physical activity [27]. Therefore
exploring this concept in patients with MM is of
interest.
Predicted attrition rates
Based on attrition rates noted in a previous pilot study
in myeloma patients recruited from UCLH [14], in
which patients were followed over a period of one year
with two follow-up visits in between, we expect that ap-
proximately a third will drop out / become ineligible)
over the course of the research (as disease relapse is in-
evitable in MM). Changes from baseline will be assessed
for all outcome measures.
Analyses
Given the exploratory nature of our study and dearth of
lifestyle data on which to power our analyses, a prag-
matic decision was made to recruit at least 138 partici-
pants, to examine the relationship between the outcome
variables.
Fatigue and bone health will be analysed using re-
peated measures (mixed modelling), over the 3 time
points (3, 6 and 12 months), after controlling for the
baseline measure of fatigue and indicators of bone
health. There will also be focus on the effect at 3 months,
analysed by linear regression.
Quality of life (FACT-G of the FACIT), and Hospital
Anxiety and Depression scale (HADS), will be converted
into their standard scores and domains and analysed
using linear regression (for the effect by 3 months) and
mixed modelling/repeated measures (for all time points).
The other outcome measures (physical and exercise cap-
acity endpoints) will also be analysed using the same
methods, as will the biochemical markers. Assessments
for each outcome will be made to determine whether
the data are normally distributed. For outcomes that are
not, even after appropriate transformations, non-
parametric methods will be used for data analyses at
specific time points.
Missing data will be dealt with using methods such as
those summarised in http://missingdata.lshtm.ac.uk/
talks/RSS_2012_04_18_James_Carpenter.pdf, or chained
equations [28].
Data storage and retention
Data storage and handling will be carried out according
to Good Clinical Practice requirements and will be kept
for at least 10 years from the date of completion of the
project.
Ethical consideration and dissemination
All participants recruited in this study will provide
written informed consent. They will also be reminded
that their participation is voluntary and that they have
the right to withdraw at any stage without giving a
reason, with their usual medical care not being af-
fected in any way.
The results of this study will be disseminated to the
academic and clinical audiences in medical, public health
and behavioural science meetings and conferences. In
addition, the results will be presented in MDT meetings
at UCLH, Royal Free and St Bartholomew’s sites. Cancer
Research UK will also publish the findings on their web-
site and communicate them to their stakeholders. More-
over, the findings from the study will be presented at
national and international haematology meetings, and
published in a relevant peer-reviewed journal.
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UCL Press office will assist with helping to disseminate
the results to the general public and policy makers via
press releases.
Discussion
This study will be the first one to prospectively follow a
cohort of patients with Multiple Myeloma in order to
document changes in physical activity and sedentary
time and fitness, and associations between these and
well-being, bone health and fatigue (along with a num-
ber of other physical and clinical outcomes). The longi-
tudinal design allows us to investigate and hopefully
identify critical points in the disease trajectory at which
physical activity may be of optimal benefit to patients
with MM.
The study will shed light on what factors determine
activity participation in this patient group and will also
help to identify the characteristics of patients who are
most likely to benefit from taking part in PA. The use of
accelerometers will provide further and objective evi-
dence as to the intensity, volume and frequency of PA
that would be of optimal benefit to patients with MM.
Finally, the study will address the gap in knowledge
about how much and what kind of lifestyle advice pa-
tients with myeloma seek and deem to be necessary to
improve their cancer management and quality of life
after cancer treatment. It is intended that the project de-
termines the scope for future interventions and provides
a valuable source of information for lifestyle recommen-
dations for patients with MM.
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